Do soft mist inhalers hold the key to faster inhalation drug development?
Authors: Wilbur de Kruijf, Bernhard Müllinger
Publication: OnDrug Delivery, No 131, April 11th 2022
Abstract: The rise of the biopharmaceutical segment has increased the value of the inhalation sector, with more and more drug developers exploring inhalation as an alternative delivery mechanism to the parenteral approach traditionally used for biologics.
While inhalation is an ideal delivery pathway for a wide range of drugs, pharmaceutical companies face a range of challenges when developing effective inhalation drug products.
In fact, the cost and complexity of developing and customising inhalation devices and formulations are often too high for biologics or drug products requiring large dosages.
Soft mist inhaler (SMI) technology has evolved in recent years alongside traditional inhalation device technologies with a range of different technical capabilities. Does SMI technology offer the opportunity to address this issue and support the expansion of the inhalation segment?
